Works Cited

1. Worobey M, Gemmel M, Teuwen DE, et al. Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960. Nature. 2008;455(7213):661-664.

2. Bailes E, Gao F, Bibollet-Ruche F, et al. Hybrid origin of SIV in chimpanzees. Science. 2003;300(5626):1713.

3. Centers for Disease Control and Prevention. HIV-2 infection surveillance—United States, 1987–2009. MMWR. 2011;60(29); 985-988.

4. Urden LD, Stacy KM, Lough ME. Critical Care Nursing: Diagnosis and Management. 8th ed. Maryland Heights, MO: Elsevier; 2017.

5. Joint United Nations Programme on HIV/AIDS. UNAIDS Data 2019. Geneva: UNAIDS; 2019.

6. U.S. Department of State. U.S. Efforts to Combat the HIV/AIDS Pandemic in Africa: A Special Briefing by Randall Tobias, U.S. Global AIDS Coordinator [Archive]. Available at https://2001-2009.state.gov/s/gac/rl/rm/47810.htm. Last accessed February 18, 2020.

7. U.S. Department of State. About Us - PEPFAR. Available at https://www.state.gov/about-us-pepfar/. Last accessed February 18, 2020.

8. U.S. Congress. S. 1545 (113th): PEPFAR Stewardship and Oversight Act of 2013. Available at https://www.govtrack.us/congress/bills/113/s1545/text. Last accessed February 18, 2020.

9. HIV.gov. U.S. Statistics: Fast Facts. Available at https://www.hiv.gov/hiv-basics/overview/data-and-trends/statistics. Last accessed February 18, 2020.

10. Centers for Disease Control and Prevention. HIV Surveillance Report, 2018 (Preliminary); vol. 30. Available at https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-2018-vol-30.pdf. Last accessed February 18, 2020.

11. Washington State Department of Health, Office of Infectious Disease Assessment Unit. Washington State HIV Surveillance Semiannual Report: 2016 Edition. Available at https://www.doh.wa.gov/Portals/1/Documents/Pubs/150-030-HIVSurveillanceSemiAnnualReport1-2016.pdf. Last accessed February 18, 2020.

12. Simon V, Ho DD, Karim Q A. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet. 2006;368(9534):489-504.

13. Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. N Engl J Med. 1998;339(1):33-39.

14. U.S. Department of Health and Human Services, Agency for Healthcare Research and Quality. The Guide to Clinical Preventive Services, 2014. Available at https://www.ahrq.gov/sites/default/files/wysiwyg/professionals/clinicians-providers/guidelines-recommendations/guide/cpsguide.pdf. Last accessed February 18, 2020.

15. U.S. Preventive Services Task Force. Human Immunodeficiency Virus (HIV) Infection: Screening. Available at https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/human-immunodeficiency-virus-hiv-infection-screening1. Last accessed February 18, 2020.

16. Branson BM, Owen SM, Wesolowski LG, et al. Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations. Available at https://stacks.cdc.gov/view/cdc/23447. Last accessed February 18, 2020.

17. Revised Code of Washington. Chapter 70.24.330 HIV Testing-Consent, Exceptions. Available at https://apps.leg.wa.gov/rcw/dispo.aspx?cite=70.24.330. Last accessed February 18, 2020.

18. JUSTIA US Law. 2016 Revised Code of Washington Title 70 – Public Health and Safety 70.24 Control and Treatment of Sexually Transmitted Diseases. 70.24.330 HIV Testing – Consent, Exceptions. Available at https://law.justia.com/codes/washington/2016/title-70/chapter-70.24/section-70.24.330/. Last accessed February 18, 2020.

19. Hanssen I. An intercultural nursing perspective on autonomy. Nursing Ethics. 2004;11(1):28-41.

20. Carrese J, Rhodes L. Western bioethics on the Navaho reservation: benefit or harm? JAMA. 1995;274:826-829.

21. Rashad AM, MacVane Phipps F, Haith-Cooper M. Obtaining informed consent in an Egyptian research study. Nursing Ethics. 2004;11(4):394-399.

22. Yick A, Berthold SM. Conducting research on violence in Asian American communities: methodological issues. Violence and Victims. 2005;20(6):661-677.

23. Washington State Legislature. Washington Administrative Code Chapter 246-100 Communicable and Certain Other Diseases. Available at https://apps.leg.wa.gov/wac/default.aspx?cite=246-100. Last accessed February 18, 2020.

24. King County. Summary of Washington State HIV/AIDS Reporting Requirements and Regulations. Available at https://www.kingcounty.gov/depts/health/communicable-diseases/hiv-std/patients/epidemiology/hiv-reporting-requirements.aspx. Last accessed February 18, 2020.

25. Branson BM, Handsfield HH, Lampe MA, et al. H. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR14):1-17.

26. Centers for Disease Control and Prevention, Health Resources and Services Administration, National Institutes of Health, American Academy of HIV Medicine, Association of Nurses in AIDS Care, International Association of Providers of AIDS Care, National Minority AIDS Council, Urban Coalition for HIV/AIDS Prevention Services. Recommendations for HIV Prevention with Adults and Adolescents with HIV in the United States, 2014: Summary for Clinical Providers. Rockville, MD: U.S. Department of Health and Human Services; 2014.

27. Centers for Disease Control and Prevention. HIV and Its Transmission FactSheet. Available at https://www.tdi.texas.gov/pubs/videoresource/fshiv.pdf. Last accessed February 18, 2020.

28. Jin F, Jansson J, Law M, et al. Per-contact probability of HIV transmission in homosexual men in Sydney in the era of HAART. AIDS. 2010;24(6):907-913.

29. Boily MC, Baggaley RF, Wang L, et al. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis. 2009;9(2):118-129.

30. Weller SC, Davis-Beaty K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev. 2002;1:CD003255.

31. Giannou FK, Tsiara CG, Nikolopoulos GK, et al. Condom effectiveness in reducing heterosexual HIV transmission: a systematic review and meta-analysis of studies on HIV serodiscordant couples. Expert Rev Pharmacoecon Outcomes Res. 2016;16(4):489-499.

32. Smith DK, Herbst JH, Zhang X, Rose CE. Condom effectiveness for HIV prevention by consistency of use among men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2015;68(3):337-344.

33. Millett G, Malebranche D, Mason B, Spikes P. Focusing "down low:" bisexual black men, HIV risk and heterosexual transmission.J Natl Med Assoc. 2005;97(7 Suppl):52S-59S.

34. Centers for Disease Control and Prevention. Oral Sex and HIV Risk. Available at https://www.cdc.gov/hiv/risk/oralsex.html. Last accessed February 18, 2020.

35. Lab Tests Online. HIV Viral Load. Available at https://labtestsonline.org/tests/hiv-viral-load. Last accessed February 18, 2020.

36. Centers for Disease Control and Prevention. HIV transmission through transfusion—Missouri and Colorado, 2008. MMWR. 2010;59(41):1335-1339.

37. Leveton LB, Sox HC Jr, Stoto MA (eds). HIV and the Blood Supply: An Analysis of Crisis Decisionmaking. Washington, DC: National Academies Press; 1995.

38. Centers for Disease Control and Prevention. National Center for Infectious Diseases. Exposure to Blood: What Healthcare Personnel Need to Know. Available at https://www.cdc.gov/HAI/pdfs/bbp/Exp_to_Blood.pdf. Last accessed February 18, 2020.

39. Levesque A, Bruneau J, Jutras-Aswad D, et al. Psychological distress increases needle sharing among cocaine users: results from the COSMO Study. J Addict Res Ther. 2014; S10:003.

40. Centers for Disease Control and Prevention. Syringe Disinfection for Injection Drug Users. The Academy for Educational Development, 2004.

41. Siberry GK. Preventing and managing HIV infection in infants, children, and adolescents in the United States. Pediatr Rev. 2014;35(7):268-286.

42. Flynn PM, Abrams EJ. Prevention of Mother-to-Child HIV Transmission in Resource-Limited Settings. Available at https://www.uptodate.com/contents/prevention-of-mother-to-child-hiv-transmission-in-resource-limited-settings. Last accessed February 18, 2020.

43. Centers for Disease Control and Prevention. HIV and Pregnant Women, Infants, and Children. Available at https://www.cdc.gov/hiv/group/gender/pregnantwomen/index.html. Last accessed February 18, 2020.

44. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. Available at https://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf. Last accessed February 18, 2020.

45. Ahn J, Cohen SM. Transmission of human immunodeficiency virus and hepatitis C virus through liver transplantation. Liver Transpl. 2008;14(11):1603-1608.

46. Centers for Disease Control and Prevention. HIV transmitted from a living organ donor—New York City, 2009. MMWR. 2011;60(10):297-301.

47. Boyarsky BJ, Durand CM, Palella FJ Jr, Segev DL. Challenges and clinical decision-making in HIV-to-HIV transplantation: insights from the HIV literature. Am J Transplant. 2015;15(8):2023-2030.

48. Muller E, Barday Z, Mendelson M, Kahn D. HIV-positive-to-HIV-positive kidney transplantation: results at 3 to 5 years. N Engl J Med. 2015;372(7):613-620.

49. U.S. Department of Health and Human Services. Organ Procurement and Transplantation Network. HOPE Act. Available at https://optn.transplant.hrsa.gov/learn/professional-education/hope-act/. Last accessed February 18, 2020.

50. U.S. National Library of Medicine. ClinicalTrials.gov. HOPE in Action Prospective Multicenter, Clinical Trial of Deceased HIVD+ Kidney Transplants for HIV+ Recipients. Available at https://clinicaltrials.gov/ct2/show/NCT03500315. Last accessed February 18, 2020.

51. Congress.Gov. H.R.6458 – National Organ Transplant Act Amendments of 2018. Available at https://www.congress.gov/bill/115th-congress/house-bill/6458. Last accessed February 18, 2020.

52. Centers for Disease Control and Prevention. Occupational HIV Transmission and Prevention Among Health Care Workers. Available at https://www.cdc.gov/hiv/pdf/workplace/cdc-hiv-healthcareworkers.pdf. Last accessed February 18, 2020.

53. Kuhar DT, Henderson DK, Struble KA, et al. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infect Control Hosp Epidemiol. 2013;34(9):875-892.

54. UNAIDS. HIV-Related Opportunistic Diseases: UNAIDS Technical Update. Available at http://data.unaids.org/Publications/IRC-pub05/opportu_en.pdf. Last accessed February 18, 2020.

55. Breuner CC, Mattson G, American Academy of Pediatrics Committee on Psychosocial Aspects of Child and Family Health. Sexuality education for children and adolescents. Pediatrics. 2016;138(2):e1-e11.

56. Office of AIDS Research Advisory Council Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Available at https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Last accessed February 18, 2020.

57. U.S. Food and Drug Administration. FDA-Approved HIV Medicines. Available at https://aidsinfo.nih.gov/education-materials/fact-sheets/21/58/fda-approved-hiv-medicines. Last accessed February 18, 2020.

58. .S. Department of Health and Human Services. HIV/AIDS News. Approval of Maraviroc. Available at https://aidsinfo.nih.gov/news/800/approval-of-maraviroc. Last accessed February 18, 2020.

59. U.S. Department of Health and Human Services. AIDSinfo. FDA Approves the First Integrase Inhibitor, Raltegravir. Available at https://aidsinfo.nih.gov/news/803/fda-approves-the-first-integrase-inhibitor--raltegravir---october-12--2007. Last accessed February 18, 2020.

60. U.S. Food and Drug Administration. FDA Approves New Drug to Treat HIV Infection [Archive]. Available at https://wayback.archive-it.org/7993/20170112023854/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm364744.htm. Last accessed February 18, 2020.

61. Larson KB, Wang K, Delille C, Otofokun I, Acosta EP. Pharmacokinetic enhancers in HIV therapeutics. Clin Pharmacokinet. 2014;53(10):865-872.

62. INSIGHT START Study Group, Lundgren JD, Babiker AG, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795-807.

63. TEMPRANO ANRS 12136 Study Group, Danel C, Moh R, et al. A Trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373(9):808-822.

64. Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at https://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Last accessed February 18, 2020.

65. Luetkemeyer A. HIV InSite Knowledge Base Chapter: Tuberculosis and HIV. Available at http://hivinsite.ucsf.edu/InSite?page=kb-05-01-06. Last accessed February 18, 2020.

66. Centers for Disease Control and Prevention, National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. Treating opportunistic infections among HIV-infected adults and adolescents. MMWR Recomm Rep. 2009;58(RR4):1-207.

67. U.S. Department of Health and Human Services, Health Resources and Services Administration. Guide for HIV/AIDS Clinical Care: 2014 Edition. Rockville, MD: U.S. Department of Health and Human Services, 2014.

68. Joint United Nations Programme on HIV/AIDS (UNAIDS), 2017. Available at https://www.unaids.org/sites/default/files/media_asset/when-women-lead-change-happens_en.pdf. Last accessed February 18, 2020.

69. Kaiser Family Foundation. Women and HIV/AIDS in the United States. Available at https://www.kff.org/hivaids/fact-sheet/women-and-hivaids-in-the-united-states/. Last accessed February 18, 2020.

70. Agency for Health Care Policy and Research. Many People with AIDS Change Their Minds About End-of-Life Care as the Disease Progresses. Available at http://archive.ahrq.gov/research/apr99/ra11.htm. Last accessed February 18, 2020.

71. Centers for Disease Control and Prevention. HIV Among Women. Available at https://www.cdc.gov/hiv/group/gender/women/. Last accessed February 18, 2020.

72. Centers for Disease Control and Prevention. National Center for Health Statistics. Leading Causes of Death. Available at https://www.cdc.gov/nchs/fastats/leading-causes-of-death.htm. Last accessed February 18, 2020.

73. Hewitt RG, Parsa N, Gugino L. The role of gender in HIV progression. BETA. 2001;14(1):13-16.

74. Jarrin I, Geskus R, Bhaskaran K, et al. Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women. Am J Epidemiol. 2008;168(5):532-540.

75. Report of the Office of Research on Women's Health. Available at https://orwh.od.nih.gov/resources/pdf/2-ORWH-ACRWH-Biennial-Report-FY13-14.pdf. Last accessed February 18, 2020.

76. MedlinePlus. HIV/AIDS in Women. Available at https://medlineplus.gov/hivaidsinwomen.html. Last accessed February 18, 2020.

77. American College of Obstetricians and Gynecologists. Practice bulletin no. 157: cervical cancer screening and prevention. Obstet Gynecol. 2016;127(1):e1-e20.

78. Maini MK, Gilson RJ, Chavda N, et al. Reference ranges and sources of variability of CD4 counts in HIV-seronegative women and men. Genitourin Med. 1996;72:27-31.

79. Heffron R, Donnell D, Rees H, et al. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis. 2012;12(1):19-26.

80. Ralph LJ, McCoy SI, Shiu K, Padian NS. Hormonal contraceptive use and women's risk of HIV acquisition: a meta-analysis of observational studies. Lancet Infect Dis. 2015;15(2):181-189.

81. Haddad LB, Polis CB, Sheth AN, et al. Contraceptive methods and risk of HIV acquisition or female-to-male transmission. Curr HIV/AIDS Rep. 2015;11(4):447-458.

82. Blackstock OJ, Tate JP, Akgün KM, et al. Sex disparities in overall burden of disease among HIV-infected individuals in the Veterans Affairs healthcare system. J Gen Intern Med. 2013;28(Suppl 2):S577-S582.

83. Centers for Disease Control and Prevention. HIV Among Pregnant Women, Infants, and Children. Available at https://www.cdc.gov/hiv/group/gender/pregnantwomen/index.html. Last accessed February 18, 2020.

84. Centers for Disease Control and Prevention. Revised surveillance case definition for HIV infection—United States, 2014. MMWR. 2014;63(RR3):1-10.

85. Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Available at https://aidsinfo.nih.gov/contentfiles/lvguidelines/PediatricGuidelines.pdf. Last accessed February 18, 2020.

86. Centers for Disease Control and Prevention. Fact Sheet: HIV Among Persons Aged 50 and Older. Available at https://www.cdc.gov/hiv/group/age/olderamericans/index.html. Last accessed February 18, 2020.

87. Pilowsky DJ, Wu LT. Sexual risk behaviors and HIV risk among Americans aged 50 years or older: a review. Subst Abuse Rehabil. 2015;6:51-60.

88. U.S. Food and Drug Administration. Truvada for PrEP Fact Sheet: Ensuring Safe a Proper Use [Archive]. Available at https://wayback.archive-it.org/7993/20170406045104/https://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM312290.pdf. Last accessed February 18, 2020.

89. U.S. Food and Drug Administration. FDA Approves Second Drug to Prevent HIV Infection as Part of Ongoing Efforts to End the HIV Epidemic. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-second-drug-prevent-hiv-infection-part-ongoing-efforts-end-hiv-epidemic. Last accessed February 18, 2020.

90. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.N Engl J Med. 2010;363:2587-2599.

91. Centers for Disease Control and Prevention. US Public Health Service. Preexposure Prophylaxis for the Prevention of HIV Infection in the United States – 2017 Update: A Clinical Practice Guideline. Available at https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf. Last accessed February 18, 2020.

92. U.S. Department of Health and Human Services. HIV Vaccine Development. Available at https://www.niaid.nih.gov/diseases-conditions/hiv-vaccine-development. Last accessed February 18, 2020.

93. U.S. Department of Health and Human Services. What is a Therapeutic HIV Vaccine? Available at https://aidsinfo.nih.gov/understanding-hiv-aids/fact-sheets/19/91/what-is-a-therapeutic-hiv-vaccine-/. Last accessed February 18, 2020.

94. IAVI. Available at https://www.iavi.org/. Last accessed February 18, 2020.

95. International Partnership for Microbicides. What Are Microbicides? Available at https://www.ipmglobal.org/why-microbicides/arv-based-microbicides-and-how-they-work/what-are-microbicides. Last accessed February 18, 2020.

96. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168-1174.

97. Kann L, McManus T, Harris WA, et al. Youth risk behavior surveillance—United States, 2017. MMWR. 2018;67(8):1-114.

98. Breuner CC, Mattson G, American Academy of Pediatrics Committee on Psychosocial Aspects of Child and Family Health. Sexuality education for children and adolescents. Pediatrics. 2016;138(2):e1-e11.

99. Centers for Disease Control and Prevention. HIV/AIDS Prevention Research Synthesis Project. Available at https://www.cdc.gov/hiv/dhap/prb/prs. Last accessed February 18, 2020.

100. Washington State Legislature. Washington Administrative Code Chapter 246-101 Notifiable Conditions. Available at https://apps.leg.wa.gov/WAC/default.aspx?cite=246-101. Last accessed February 18, 2020.

101. U.S. Food and Drug Administration. FDA Approves New HIV Treatment for Patients with Limited Treatment Options. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-new-hiv-treatment-patients-limited-treatment-options. Last accessed July 16, 2020.

102. U.S. Food and Drug Administration. FDA Approves First Extended-Release, Injectable Drug Regimen for Adults Living with HIV. Available at https://www.fda.gov/news-events/press-announcements/fda-approves-first-extended-release-injectable-drug-regimen-adults-living-hiv. Last accessed February 25, 2021.

Evidence-Based Practice Recommendations Citations

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Bethesda, MD: Department of Health and Human Services; 2020. Available at https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Last accessed March 27, 2020.



Privacy Policy
Copyright © 2020 CE Resource, P.O. Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.